Trobix Innovation Ltd., a Netanya, Israel-based biotechnology company developing therapies to remove the threat of antimicrobial resistance, closed a US $ 3M Series A funding.
The round was led by Chartered Opus.
The company intends to use the funds to advance its antimicrobial resistance platform technology and to further the pre-clinical development of the its lead product, TBX101.
Led by Dr. Adi Elkeles, Founder & CEO, Trobix Bio is a preclinical biotechnology company, developing therapies to remove the threat of antimicrobial resistance, a global crisis strongly evidenced nowadays during the COVID-19 Pandemic. The company leverages its ActiSense™ and GoTrap™ technologies to develop phage-based products that can effectively deliver DNA to a wide range of bacterial pathogens, and actively sensitize these pathogens to antibiotics. Its lead product, TBX101, aims to treat patients carrying gut antimicrobial resistant bacteria, resulting in an antibiotic sensitive gut microbiome.